[Decrease in the corticosterone content in rat blood after intraperitoneal or per os administration of histones].

V I Tiulenev; G V Tiuleneva

PubMed · 7974831

[Decrease in the corticosterone content in rat blood after intraperitoneal or per os administration of histones].

Abstract

The influence of histones, protamine, pronase E and albumin on the corticosterone amount in the blood of rats has been studied. It is shown that injection of 10 and 100 (or 500) mkg of histones per 100 g of body weight leads to a decrease of the corticosterone amount in the blood 24 and 5 h (respectively) later. Irrespective of the injection way (intra-abdominal or per os), a dose of 500 mkg of histones per 100 g of body weight decreases the corticosterone amount in blood by 96%, already 5 h later and, after 24 h the corticosterone amount is practically undetermined. In all cases regeneration of the corticosterone amount in blood is observed after 48 h, and besides, the regeneration extent is inversely proportional to the extent of the corticosterone amount decrease in the first hours of the histone injection. After digestion of 500 mkg of histones with 10 mkg of pronase E during 10 min at 37 degrees C and following injection of this mixture, the corticosterone amount in blood decreases but to much less extent than with injection of the same quantity of intact histones. After more intensive digestion (500 mkg of histones with 50 mkg of pronase E during 30 min at 37 degrees C), histones do not decrease the corticosterone amount in blood but they increase it 5 h after the injection, and then exert no influence on the corticosterone amount. The protamine injection does not influence the corticosterone amount in the first hours but increases it 48 h later. Injection of pronase E and albumin increases the corticosterone amount in blood.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Administration, Oral Animals Corticosterone Histones Injections, Intraperitoneal Male Pronase Protamines Rats Serum Albumin Thyroxine English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

V I Tiulenev, G V Tiuleneva. [Decrease in the corticosterone content in rat blood after intraperitoneal or per os administration of histones].. https://pubmed.ncbi.nlm.nih.gov/7974831/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

High dose oral tolerance in ovalbumin TCR-transgenic mice: systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis.

The immune response to oral Ag administration, including the development of oral tolerance, was explored with the use of OVA TCR-transgenic mice. Feeding high doses of OVA enhanced IFN-gamma production in the Peyer's patches, but induced tolerance in the peripheral lymphoid tissues marked by suppressed proliferative and cytokine responses. Systemic administration of Abs to IL-12 (anti-IL-12) simultaneous with Ag feeding modestly enhanced the degree of tolerance in the peripheral lymphoid tissues, as shown by increased suppression of proliferative responses after in vitro restimulation, and secondary responses in the popliteal lymph nodes following in vivo challenge and in vitro restimulation. Systemic anti-IL-12 treatment was associated with augmented TGF-beta production and T cell apoptosis in both Peyer's patches and peripheral lymphoid tissues. Cell mixing studies and proliferation assays in the presence of anti-TGF-beta provided evidence that the increased suppression of responses induced by anti-IL-12 was due primarily to the secretion of TGF-beta. These findings suggest that IL-12 negatively regulates two of the main mechanisms of oral tolerance, TGF-beta production and clonal deletion via apoptosis. in addition, they suggest that the combination of oral Ag feeding and systemic anti-IL-12 administration may be of benefit in the treatment of autoimmune diseases.

Administration, Oral↗

PubMed1996

Effect of tamoxifen on measurements of hemostasis in healthy women.

BACKGROUND: Tamoxifen citrate is being evaluated for primary prevention of breast cancer, but this drug with estrogen-like properties may cause changes in the hemostatic system that would increase the risk of thrombosis. METHODS: Women who had undergone hysterectomy were consecutively enrolled in the placebo-controlled, randomized, double-blind Breast Carcinoma Chemoprevention Tamoxifen Study, which was designed to evaluate the efficacy of oral tamoxifen citrate (20 mg/d). Our substudy of hemostasis and lipid measurements included the first 68 consecutive women assigned to tamoxifen (n = 31) or placebo (n = 37). Blood specimens were obtained before treatment and after 1,2,4, and 6 months of treatment. Measurements included blood cell counts, lipid levels, coagulation activation markers, clotting factors, and anticoagulant and fibrinolysis proteins. RESULTS: Hematocrit and hemoglobin and platelet levels fell slightly but significantly in women treated with tamoxifen. No between-treatment differences were observed in any of the clotting factors. Naturally occurring anticoagulant proteins such as antithrombin and protein C fell slightly in women treated with tamoxifen. However, no significant changes were observed in any of the markers of activated coagulation or fibrinolysis (fibrinopeptide A, prothrombin fragment 1 + 2, thrombin-antithrombin complex, D-dimer). Total and low-density lipoprotein cholesterol levels fell significantly in women treated with tamoxifen. CONCLUSIONS: Tamoxifen induced a modest decrease in anticoagulant proteins, but without biochemical signs of activation of coagulation and fibrinolysis. Tamoxifen improved the lipid profile and induced changes in blood cell counts, which should determine an improvement in blood rheologic factors. These preliminary findings seem to justify continuation of the double-blind study in healthy women, but only direct comparison of thromboembolic complications in the 2 treatment groups will establish whether tamoxifen carries a risk of thrombosis.

Administration, Oral↗

PubMed1996

Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance.

We report here a murine model for experimental chronic colitis where administration of trinitrobenzene sulfonic acid (TNBS) in 50% ethanol induced inflammation of large intestine in susceptible (C3H/HeJ and BALB/c) but not resistant (C57BL/6 and DBA/2) mouse strains. We queried whether mucosal trinitrophenyl (TNP)-specific B cell responses were induced in mice with TNBS-induced colitis, and if induction of tolerance to TNBS by oral administration of this hapten protected mice from development of colitis. Isotypes and subclasses of polyclonal and TNP-specific Ab-forming cells (AFC) were assessed in mucosal and peripheral lymphoid tissues of C3H/HeJ mice with TNBS-induced colitis. Increased numbers of IgA- and IgG-secreting cells were found in the inflamed colon lamina propria. Inflamed colonic tissue also contained high frequencies of IgG anti-TNP AFC (predominantly of IgG1, IgG2a, and IgG2b subclasses); however, anti-TNP responses in noninflamed mucosal tissues of mice with colitis exhibited dominant IgA and IgM with low IgG anti-TNP responses. CD4+ T cells stimulated with TNP-splenocytes produced more IFN-gamma and less IL-4, suggesting a Th1-type response. Oral administration of TNBS before induction of colitis markedly decreased mucosal anti-TNP responses and completely inhibited anti-TNP IgG2a and IgG2b responses. Control mice did not show inhibition of anti-TNP AFC responses or TNBS-induced colitis. Intracolonic sensitization of susceptible C3H/HeJ mice with TNBS induces a localized IgG anti-TNP B cell response in the inflamed tissue, whereas prior oral administration of TNBS results in unresponsiveness to this agent and protects mice from development of TNBS-induced colitis.

Administration, Oral↗